All In Biotech

Drug Trial Radar · NCT00024427

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Jun 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Feb 2001

Primary completion

Feb 2006

Sponsor

Lead sponsor
Wellstat TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is more effective in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus triacetyluridine with that of gemcitabine in treating patients who have locally advanced or metastatic pancreatic cancer that cannot be treated with surgery.

Conditions

  • Drug/Agent Toxicity by Tissue/Organ
  • Pancreatic Cancer

Interventions

  • fluorouracilDrug

    High dose 5-FU

  • gemcitabine hydrochlorideDrug

    Normal dose to treat pancreatic cancer

  • triacetyluridineDrug

    6 grams (12 tablets)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer PatientsTime frame: Disease progression

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • Brookwood Medical Center

    Birmingham, Alabama

  • Comprehensive Cancer Center at University of Alabama at Birmingham

    Birmingham, Alabama

  • Providence Saint Joseph Medical Center - Burbank

    Burbank, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Scripps Cancer Center at Scripps Clinic

    La Jolla, California

  • Northwest Oncology and Hematology Associates

    Coral Springs, Florida

  • Florida Cancer Specialists - World Plaza

    Fort Myers, Florida

  • Memorial Cancer Institute at Memorial Regional Hospital

    Hollywood, Florida

  • Florida Oncology Associates - South Side

    Jacksonville, Florida

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Florida Cancer Institute - New Port Richey

    New Port Richey, Florida

  • St. Joseph's Hospital

    Savannah, Georgia

  • Cancer Care Center

    New Albany, Indiana

  • Cancer Center at Greater Baltimore Medical Center

    Baltimore, Maryland

  • Wellstat Therapeutics

    Gaithersburg, Maryland

  • CCOP - Metro-Minnesota

    Saint Louis Park, Minnesota

  • Capitol Comprehensive Cancer Care Clinic

    Jefferson City, Missouri

  • David C. Pratt Cancer Center at St. John's Mercy

    St Louis, Missouri

  • University of New Mexico Cancer Research and Treatment Center

    Albuquerque, New Mexico

  • Queens Medical Associates, PC

    Fresh Meadows, New York

  • New York Weill Cornell Cancer Center at Cornell University

    New York, New York

  • Summit Oncology Associates

    Akron, Ohio

  • Penn State Cancer Institute at Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Fox Chase - Temple Cancer Center

    Philadelphia, Pennsylvania

  • Cancer Centers of the Carolinas - Eastside

    Greenville, South Carolina

  • Corpus Christi Cancer Center

    Corpus Christi, Texas

  • Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • Regional Cancer Care at Thunder Bay Regional Health Sciences Centre

    Thunder Bay, Ontario, Canada

  • McGill Cancer Centre at McGill University

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.